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Alzheimer’s disease (AD) is the most common form of dementia affecting millions of
individuals, including family members who often take on the role as caregiver. This
debilitating disease reportedly consumes 8% of the total United States healthcare
expenditure, with medical and nursing outlays accounting for an estimated $290 billion.
Cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists have
historically been the most widely used pharmacologic therapies for patients with AD,
however, these drugs are not curative. This review discusses the epidemiology,
pathophysiology, risk factors, presentation, and current treatment of AD followed by the
role of the novel monoclonal antibody, aducanumab, in treatment of AD. Currently
aducanumab is the only Food and Drug Administration (FDA) approved drug that acts to
slow progression of this disease. Aducanumab is an anti-amyloid drug which functions by
selectively binding amyloid aggregates in both the oligomeric and fibrillar states. Studies
show aducanumab may help to restore neurological function in patients with AD by
reducing beta-amyloid plaques and reestablishing neuronal calcium permeability.
However, there is concern the magnitude of this drug’s benefit may only be statistically
significant and not clinically significant. Despite this skepticism, aducanumab has proven
to significantly decrease amyloid in all cortical brain regions examined. In summary,
aducanumab has provided hope for those working toward the goal of providing patients a
safe and viable treatment option in the management of AD.

INTRODUCTION
Alzheimer’s disease (AD) is defined as a progressive degenerative brain disease that insidiously takes over the memories, cognitive function, and livelihood of those diagnosed.
AD was first described as a serious cortical disease by Alois
Alzheimer after finding massive neuronal loss and amyloid
plaques in the brain of a patient who suffered from alterations in personality and loss of memory.1
Microscopic changes in the brain occur long before first
onset of symptoms and thus long before diagnosis. The
severity of symptoms is classified based on the level of interference with one’s ability to perform everyday tasks. Diagnosis of AD lies on a spectrum ranging from preclinical
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AD with little to no symptoms and extending to severe debilitating AD.2 Early stages of symptomatic AD first affects
cognitive function. What begins as subtle difficulty learning
and recalling new information, insidiously progresses to
episodes of disorientation and confusion. Later stages manifest with more severe symptoms such as changes in behavior and mood along with physical symptoms such as difficulty swallowing and speaking.2 The duration of each stage
and rate of progression varies and is influenced by factors
such as genetics, age, and predisposing conditions.3
As the disease progresses, patients are slowly stripped
of their independence resulting in an inevitable reliance
on care givers. An estimated 83% of care-givers to older
adults in the United states (US) are unpaid family members,
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friends or others.2 The level of responsibility placed on the
care givers of AD patients often requires additional help
from health care and support from social institutions.4 AD
has been reported to consume 8% of the total US healthcare
expenditure, with medical and nursing outlays accounting
for an estimated $290 billion.5 AD patients account for
twice the amount of hospital stays as compared to other elderly citizens and increased stays in skilled nursing facilities and home healthcare visits.2 Development of a curative
treatment stands to not only impact patients and their families, but also the healthcare system and overall economy.

METHODS
The present investigation is a narrative review. In 2021,
a comprehensive search was performed using the PubMed
database for studies related to the topic of aducanumab for
AD. We searched the following keywords: AD, aducanumab,
Aduhelm, dementia, clinical trials, Emerge, Engage. Priority
for inclusion was given to recent manuscripts (within the
last three years), but relevant papers older than three years
were also included. An attempt to search for, use, and cite
primary manuscripts whenever possible was also made.
This article, therefore, is based on previously conducted
studies and does not contain any new studies with human
participants or animals performed by any of the authors.

EPIDEMIOLOGY
AD is the most common form of dementia. According to
the World Health Organization (WHO), around 50 million
people worldwide have dementia of which AD is thought to
contribute to 60-80% of cases. While some cases are pure
AD, the greater majority are mixed dementias further complicating early recognition and diagnosis.6 Of the mixed dementias, vascular dementia and Lewy body dementia are
the most common.6
According to the Alzheimer’s Association, 1 in 9 Americans aged 65 or older has AD. An estimated 6.2 million
Americans 65 years or older have AD in the year 2021.2 At
age 45, an estimated lifetime risk for AD was found to be 1
in 5 (20%) for women and 1 in 10 (10%) for men; the risk
further increases after the age of 45.3 Women appear to be
diagnosed with AD more than men; almost two-thirds of
Americans diagnosed with AD are women.7 This observed
difference has varied throughout different studies and regions and is therefore suggested to be due to women’s average longer lifespan. As for racial and ethnic differences,
underrepresented groups appear to demonstrate a higher
prevalence of AD in comparison to the white population.7
A reported 18.6% of African Americans and 14% of Hispanics age 65 and older have AD compared with 10% of Caucasian seniors.7 However, studies assessing health and socioeconomic factors suggests racial and ethnic differences
in dementia risk do not persist.3 This suggests healthcare
disparities and socioeconomic factors play a stronger role
than that of ethnicity and race.
According to the Center of Disease Control and Protection (CDC) data, the overall geriatric population is projected
to grow from 420 million to 1 billion from the year 2000 to

2030.8 As for AD, by the year 2050, a projected 12.7 million Americans age 65 and older are expected to be diagnosed. 2 With a growing elderly population and projected
AD growth, focusing on better management of risk factors
and potential treatment is of the utmost importance.

RISK FACTORS
AGE

Age has been demonstrated in multiple studies to be a
strong risk factor for the development of AD.9,10 One study
reported a 19% increase in prevalence in individuals aged
75-84 years. This further increases to 30-35% in those of
85 years and greater.10 Due to similarities in pathology, AD
was once thought as an accelerated form of aging.
GENETICS

Genetic predisposition to AD has been studied for years and
plays a role in the pathogenesis of both early and late onset
AD. Early-onset AD includes individuals under the age of 65
and is associated with mutations in amyloid precursor protein (APP), presenilin (PSEN) 1, and PSEN2 genes. PSEN1
has been correlated with 80% of early-onset AD compared
to 5% associated with PSEN2.11 In contrast, polymorphisms
of the apolipoprotein-E (APOE) gene have proven to be of
importance in the development of sporadic late-onset AD.12
While the ε3 allele is the most common variant, the ε4 allele
of the APOE gene has shown to be the strongest genetic risk
for the development of sporadic AD. Conversely, the ε2 allele has demonstrated a protective role in the development
of disease. 13
ACQUIRED RISK FACTORS

Various acquired risk factors have also been proven to influence the development of AD. An early-life risk factor includes level of education achieved.14 Mid to later life risk
factors include hypertension, hyperlipidemia, diabetes,
obesity, cerebrovascular disease, alcohol abuse, smoking,
traumatic brain injury (TBI), depression, and social isolation.14,15 Notably, cerebrovascular disease and dementia
share many common risk factors such as smoking and diabetes.3 Studies have found a twofold increase in the risk
of dementia following a stroke independent of cognitive
changes prior to the incident.11 A reduction in blood supply
to the cerebrum and disruption in the blood brain barrier
may predispose to amyloidogenic processes. Similarly, hypertension increases the risk of AD development due to vascular wall changes and disruption of the blood brain barrier.11
EPIGENETIC CHANGES

Many researchers hypothesize that pathologic epigenetic
changes play a role in the development of AD. A “two-hit”
hypothesis proposes the primary disruption within the associated regulatory genetic sequences is led by environmental stress.16 The second hit is a result of further stress
potentially perpetuated by poor diet, head trauma, or altered gene expression.16,17 In AD patients with a history
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of TBI, increased APP and dystrophic neurites have been
observed.10 Similarly, chronic traumatic encephalopathy
(CTE) is a neurodegenerative tauopathy thought to be secondary to repetitive head trauma. 17

PATHOPHYSIOLOGY
The neuropathology of AD is composed of positive lesions,
related to accumulation of abnormal protein deposits, and
negative lesions, due to neuronal loss and atrophy.18–20
One of the most accepted theories regarding AD is the amyloid cascade, which refers to imbalance between the production and clearance of proteins.11 Under normal conditions, APP is cleaved by α-secretase and y-secretase. When
cleaved by β-secretase and ν-secretase, beta-amyloid (Aβ)
fragments are produced and induce amyloidogenic
processes.21 Extracellular accumulations of Aβ40 and Aβ42
due to abnormal precursor processing leads to the formation of senile plaque lesions. The Aβ42 peptide has demonstrated an increased likelihood of aggregation as compared
to Aβ40, and immunohistochemistry has revealed higher
concentrations of Aβ42 in amyloid plaques of AD patients.11 In addition, phosphorylated tau proteins form
neurofibrillary tangles intraneuronally.6,11 Accumulation of
these abnormal proteins not only leads to plaque formation
but also activation of microglia and reactive gliosis of astrocytes. This ultimately leads to toxic effects on neurons
causing atrophy, neurotransmitter loss (such as acetylcholine), and eventual loss of cognitive function.6,11,18–20

PRESENTATION
AD presents insidiously and with a spectrum of symptoms
including progressive loss of memory, confusion, and disorientation. Cases may present differently and often in a
subtle progressive fashion that goes unnoticed for extended
periods of time. Symptoms are frequently first noticed by
family members and reported several years prior to a confirmatory diagnosis.21 The time until diagnosis can be further
complicated by misdiagnosis.
An amnestic presentation is most common with impaired recall of recently learned information. However,
non-amnestic findings can also be seen such as language
deficits manifesting as trouble word-finding.3,22 In addition, impaired facial recognition, spatial cognition, and object agnosia can also be seen in later disease.22 This is often
reported as getting lost in familiar places or failure to recognize objects or individuals that are familiar to them. While
these deficits may present in a subtle manner or attributed
to old age, deficits in executive functioning such as impaired reasoning, judgement, and problem solving are often
most prominent to surrounding friends and family. 22
Imaging abnormalities may be included in the presentation and diagnosis of AD. Gross anatomic changes seen
in AD include widening of sulcal spaces, narrowing of gyri,
and enlargement of lateral ventricles secondary to atrophy.6
Amyloidosis of the brain may be seen in neocortical areas
spreading to subcortical structures.11 However, AD can only
be diagnosed with complete certainty via microscopic examination after death.

Throughout the course of the disease, concomitant neuropsychiatric disturbances are often reported and elicit immense stress on care givers. Symptoms may mimic frontotemporal dementia including apathy, impulsivity, and
agitation.17,23 In more advanced stages, delusions and hallucinations can be seen. Visual hallucinations have been attributed to the loss of cholinergic innervation.24 Depressive
symptoms are also very common in AD and are reported in
about 20-30% of patients.25,26 There has long been a suggested relationship between the two, however, it remains
unclear whether depression is a risk factor or an early manifestation of the disease. Ultimately, AD presents with various symptoms in an unpredictable fashion. With improved
detection and treatment there is hope of preventing early
progression and cognitive decline.

CURRENT TREATMENT OF ALZHEIMER’S
Cholinesterase inhibitors and memantine, a N-methyl-Daspartate (NMDA) receptor antagonist, have historically
been the most widely used pharmacologic therapy for patients with AD, however, these drugs are not curative. The
cholinesterase inhibitors donepezil, rivastigmine, and
galantamine are typically administered at the diagnosis of
mild AD. Memantine is normally reserved for adjunctive
therapy in patients with moderate disease and an associated
decreased ability to complete activities of daily living.
While these drugs have been shown to enhance quality of
life by providing symptomatic therapy, they do not change
the disease progression, rate of decline, or overall pathological burden.27 Treatment regimens may be combined with
non-pharmacologic options such as aromatherapy, pet
therapy, music therapy, and individual recreational activities. The exact efficacy of these non-pharmacologic treatment strategies is uncertain as most studies are limited by
poor design, inadequate sample size, and a lack of blinding.28 The most successful evidence-based approaches are
individualized for each patient’s unique needs and response
to treatment. Some patients with mild AD may respond best
to physical, emotional, and social stimulation, while other
patients may need more involved cognitive behavioral therapy and pharmacologic therapy.27,28
A 12-Month, randomized, open-label trial conducted by
Cumbo et al29 investigated the differential effects of AD
medications on behavioral and psychological symptoms of
AD. The study suggests that memantine and rivastigmine
have the most profound effects on these symptoms with
minimal side effects in mild to moderate AD patients.29
These properties have important implications on a patient’s
course of care as behavioral symptoms are often the most
burdensome for the healthcare team or caretaker.27 Additionally, attenuating behavioral symptoms may prevent institutionalization and need for pharmacotherapy with other
supplemental drugs (e.g. selective serotonin reuptake inhibitors, atypical antipsychotics), however, literature review
of the cost-effectiveness of the drugs does remain inconclusive.30
In search of greater efficacy from pharmaceutical management, numerous clinical studies involving the combination of disease-modifying agents with cholinesterase inhibitors or memantine have been introduced. The goal of
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combination therapy for AD is to target alternative pathophysiologic pathways that are not influenced through standard of care alone. In addition to a more sophisticated
counter to the disease process, benefits of combination
therapy include the ability to utilize smaller therapeutic
doses of the equivalent monotherapy drug which may reduce costs and side effects of treatment.31 One approach,
taken by several of these disease-modifying therapies, is to
target the amyloid cascade. Some of these drugs have been
tested in phase III trials; however, they have failed to meet
the primary end point. Postulations as to why these drugs
have failed include delayed pharmaceutical introduction after which amyloid-lead destruction becomes too extensive.
Future studies can explore introducing anti-amyloid therapies earlier in the AD course, possibly before symptoms ever
develop.31 Another potential pathway to be intercepted involves tau-targeted therapy. Strategies of preventing hyperphosphorylation using both lithium and valproic acid
have been introduced, but random control trials of these
agents proved unsuccesful.32 Although these disease-modifying agents have yet to provide proof of significant deceleration of AD, they have augmented our current knowledge of the disease and have shown improved treatment
is a feasible goal. Until then, combination therapy with
cholinesterase inhibitors and memantine remains the most
efficacious option.33

ADUCANUMAB MECHANISM OF ACTION

ADUCANUMAB DRUG INFO

ADUCANUMAB PHARMACOKINETICS/
PHARMACODYNAMICS

Developers of the anti-amyloid drug aducanumab (marketed as Aduhelm) have reported positive findings in phase
III trials.34 The medication functions as a monoclonal antibody targeting Aβ fibrils and soluble oligomers that contribute to AD development. In an early phase, 165 patients
with prodromal or mild AD received variable intravenous
(IV) doses of the agent. Remarkably, amyloid plaques were
considerably decreased in all cortical brain regions examined, however, clinical effects were mostly insignificant.34,35 Still, these results undeniably showed aducanumab’s potential as an amyloid destroyer in future
therapies and inspired a myriad of research involving the
drug.
Engage and Emerge are perhaps the most well-known
phase III trials of aducanumab. Using the Clinical Dementia
Rating Scale-sum of boxes (CDR-SB) in individuals with
mild cognitive impairment (MCI) and mild dementia due to
AD, the Emerge trial showed a 22% decreased rate of cognitive decline in the group of participants receiving high-dose
aducanumab compared to that of the placebo group after 78
weeks of study. The experimental group in the Engage trial,
however, declined more rapidly than the placebo. Positron
Emission Tomography (PET) imaging in both groups
showed a dose-dependent decrease in amyloid deposition.36 After these trials, a biologics license for aducanumab
was submitted to the Food and Drug Administration (FDA).
The drug was approved in 2021. Of note, the drug has a
broad-label and is approved for patients across the full
spectrum of disease severity despite the clinical trials only
including subjects with mild disease.34–36

The logic behind anti-amyloid drug therapy can be simplified by the following: the removal of plaques disrupts the
major pathogenic process vital to the progression of AD
thus slowing development of the disease. Currently aducanumab is the only FDA approved drug that achieves this
purpose. The drug functions by selectively binding amyloid
aggregates in both the oligomeric and fibrillar states rather
than amyloid monomers.37 This binding discrimination by
the drug is what distinguishes aducanumab from its contemporary Aβ immunotherapeutic agents. The Aβ aggregates have been shown to exert neurotoxic effects while
monomeric Aβ has exhibited beneficial neurological functions.37,38 Although other monoclonal antibodies have
overlapping binding sites on amyloid, aducanumab provides unique amino acid interactions which allow for more
shallow and compact binding with minimized interactions
by the epitope scarce monomers. Conversely, the high affinity for aggregates can be explained by a greater concentration of epitopes specific for the monoclonal antibody
granting a greater affinity.38 Researchers have further investigated the binding mechanisms of aducanumab using
molecular dynamics simulation technology in hopes to further optimize selectivity, which may lead to smaller therapeutic doses and greater efficacy.39

Aducanumab dramatically reduces the generation of Aβ
oligomers through interrupting amyloid aggregation kinetics, a multistep process that includes primary nucleation
from monomeric protein and secondary nucleation on existing fibrils. Pharmacodynamic studies of aducanumab
have shown that the drug binds fibrils and targets them for
microglial-mediated removal, interrupting the bridge between neuroprotective amyloid monomers and neurotoxic
amyloid oligomers.40 Before aducanumab can achieve these
affects, however, therapeutic levels must be able to cross
the blood-brain-barrier and persistently promote amyloid
aggregate destruction. The drug reaches maximal clinical
benefit around 5 months of use due to a long half-life. Several other variables may influence the lag period including
the amount of time needed to remove amyloid plaques, individual amyloid burden, APOE ε4 genotype, age, and disease severity.39–41 This may explain why the high-dose
group in the Emerge trial resulted in the most significant decrease in the rate of cognitive decline; this group could have
had relatively more patients achieve a sustained steady
state in the brain.41

CLINICAL STUDIES ON ADUCANUMAB
PRE-CLINICAL STUDY FOR EFFICACY OF ADUCANUMAB
IN MICE

A placebo-controlled experiment in mice was carried out to
observe aducanumab’s efficacy of Aβ plaque degradation.
42 Mice were genetically modified to overexpress APP to
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enhance cerebral Aβ plaque formation. A chimeric analog
to aducanumab appropriate for mice was used to reduce
the size and number of these plaques. Non-placebo mice
were administered the aducanumab analog either acutely
or chronically. In 22-month-old mice receiving acute immunotherapy, craniotomy was performed and the aducanumab analog was applied directly to the mouse’s brain.
In those receiving chronic immunotherapy, mice were injected with the aducanumab analog once per week for 6
months beginning at 18 months of age. The mice’s brains
were imaged at the beginning and end of the experiment using fluorescent microscopy to tag Aβ plaques. Immunohistochemistry was also employed before and after treatment
to observe regulation of the following: inositol trisphosphate (IP3) receptor, NMDA receptor, ryanodine receptor
(RYR), and visinin-like-protein (VILIP)-1.42
Treatment with the aducanumab analog showed mixed
results on its ability to reduce the number of Aβ plaques in
mice. Mice that received acute treatment with aducanumab
analog experienced a greater decrease in Aβ plaques than
mice who received placebo. Acute topical treatment with
the analog was associated with a ~48% reduction in the
number of Aβ plaques, while control mice showed a ~14%
reduction in Aβ plaques (P < 0.0001). However, chronic
treatment with aducanumab analog did not show significant reduction in the number of Aβ plaques relative to the
control mice (P = 0.35). Also, despite its ability to degrade
existing plaques, acute treatment with aducanumab analog
did not show any significant effect on reducing the formation of new Aβ plaques relative to control (P = 0.98). These
findings suggest that aducanumab may be efficacious at reducing preformed Aβ plaques in patients but may not significantly prevent new Aβ plaque formation.42
This study’s findings also indicate that aducanumab may
benefit patients with AD through the replenishment of
cerebral intracellular calcium levels.42,43 Disruption in regulation of intracellular calcium is implicated in several neurodegenerative conditions such as Parkinson’s, Huntington’s, and AD. NMDA receptors are necessary for the
homeostatic maintenance of intracellular calcium in neurons, and Aβ plaques have shown to increase the clearance
of NMDA receptors from neuronal cell surfaces.43 In mice
that received chronic treatment, the aducanumab analog
was found to prevent calcium overload (P < 0.05) and increase NMDA receptors permeability to calcium relative to
controls (P < .05). The aducanumab analog used was also
found to restore sarcoendoplasmic reticulum calcium ATPase (SERCA) pump regulation which remained disrupted in
control mice (P < 0.001). These results show aducanumab
may help to restore neurological function in patients with
AD by reducing Aβ plaques and reestablishing neuronal calcium permeability.42,43
PHASE I CLINICAL TRIALS

Aducanumab’s first dose-escalation trial in humans was a
randomized, double-blind, placebo-controlled, singledose-escalation phase I clinical trial.44 The study included
53 participants, 39 received aducanumab and 14 received a
placebo. The aducanumab group received increasing doses
(0.3, 1, 3, 10, 20, 30, or 60 mg/kg) of aducanumab over the

course of the trial. Only 3 participants received the maximum 60mg/kg dose. In this study, the pharmacokinetics and
side effects of aducanumab were determined.44
Aducanumab was found to be well-tolerated up to a
dosage of 30 mg/kg. In patients who received ≤ 30 mg/kg,
the 3 most reported symptoms were headache, diarrhea,
and upper respiratory tract infection. Alzheimer’s related
imaging abnormality-edema/effusion (ARIA-E) was the
most severe side effect and was present in the 3 patients
who received the 60 mg/kg dose. Though each case of ARIAE had transient related complications, all resolved. The
pharmacokinetics of aducanumab, as determined by this
study, showed increasing doses did not significantly alter
drug half-life, rate of clearance, or volume of distribution.
Aducanumab’s pharmacokinetics were found to behave in a
linear, dose-dependent manner. The pharmacokinetic profile and observed side effects were found to be safe enough
to support future trials.44
In 2012, aducanumab entered a randomized doubleblind, placebo-controlled phase Ib clinical trial, entitled
Prime.35 In this trial, 165 individuals with mild AD or MCI
were administered 1, 3, 6, or 10 mg/kg of aducanumab once
per month for 12 months. This study measured aducanumab’s ability to reduce the size and number of Aβ
plaques as well as effects on cognitive function. These effects were evaluated using PET standard uptake volume ratio (SUVR), mini mental state examination (MMSE), and
CDR-SB. Aβ PET images were taken before starting treatment, then at 26 and 54 weeks after the first treatment.
There were 125 individuals who completed the trial.35
Aducanumab demonstrated significant benefit in the reduction of Aβ plaques in patients with mild AD or MCI in
this trial.35 SUVR scores were lower relative to baseline in
participants who received the 10, 6, and 3 mg/kg monthly
doses of aducanumab (P < 0.001). This reduction in Aβ
plaque accumulation was observed in patients receiving
treatment regardless of whether they had MCI or mild AD
and whether they were APOE ε4 carriers. Aβ plaque degradation was visible throughout the brain excluding the 2 regions where Aβ plaque formation was not anticipated: the
sub-cortical white matter and the pons.35
Results from the Prime trial indicate that aducanumab
may mitigate cognitive decline in patients with mild AD
or MCI.35,45 Participants with PET SUVR scores that decreased by >1 standard deviation below those of placebo
participants observed benefit in preservation of functioning
mental status. These cognitive benefits were not appreciable until treatment was carried out for 12 months despite
earlier detectable decreases in Aβ plaques.35 Aducanumab
was found to decrease the rate of progression of cognitive
symptoms of AD on the MMSE after one year of monthly
treatment at doses of 3 and 10 mg/kg (P < 0.05).35,45 However, patients treated with aducanumab were also observed
to have an increasing dose-dependent risk of developing
ARIA-E relative to patients receiving placebo. Forty-one
percent of participants receiving 10 mg/kg aducanumab developed ARIA-E while only 6% receiving 3 mg/kg aducanumab developed ARIA-E.35 This study found that aducanumab provides benefits in managing the mental status
of patients with Aβ plaque formation, but also increases
their risk of developing ARIA-E.35,45
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PHASE III CLINICAL TRIALS

SKEPTICISM SURROUNDING ADUCANUMAB’S EFFICACY

Two identical phase III double blind, randomized, placebocontrolled trials for the use of aducanumab to treat AD
were begun in September 2015.46 These trials were entitled
Emerge and Engage. Each patient, diagnosed with MCI or
mild AD, was administered either low-dose or high-dose
aducanumab once every 4 weeks for 18 months. Dosages
were appropriated according to whether patients carried the
APOE ε4 allele. The low dose was 3 mg/kg for carriers of the
APOE ε4 allele and 6 mg/kg for those who were non-carriers. The high dose was 6 mg/kg for carriers and 10 mg/kg
for non-carriers. Ultimately, 1,643 patients completed the
Emerge trial and 1,647 completed the Engage trial. The primary objective of these trials was to determine the effects
of aducanumab on cognition in AD patients using the CDRSB. Other tools used to measure patients’ cognitive decline
were MMSE, the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL), and the Alzheimer’s
Disease Assessment Scale-cognition sub-scale 13 (ADAScog13). Biomarkers of AD were also analyzed in central
spinal fluid, and PET scans were obtained to analyze the effects of aducanumab on Aβ and tau proteins.46
After post hoc analysis, both the Emerge and Engage trials demonstrated high-dose aducanumab reduced the total
number or size of Aβ plaques in patients relative to
placebo.47,48 Patients who received low-dose aducanumab
experienced a reduction in PET SUVR of 0.165 and 0.168
in the Emerge and Engage trials, respectively (P < 0.001).49
Patients who received high-dose aducanumab experienced
a reduction in PET SUVR of 0.272 and 0.238 in the Emerge
and Engage trials, respectively (P < 0.001).46,49 Compared to
other monoclonal antibodies (solanezumab, bapinezumab,
gantenerumab), aducanumab is the only monoclonal antiAβ antibody developed that has been shown to significantly
reduce Aβ PET SUVR in phase III clinical trials.47
Post hoc analysis of the Emerge trial indicates high-dose
aducanumab may reduce the rate of functional and cognitive decline in patients with mild AD.46–49 Results from
Emerge show aducanumab improved AD patients’ scores on
metrics of cognitive and physical function including the
neuropsychiatric inventory (NPI), CDR-SB, ADAS-Cog13,
and ADCS-ADL.47,50 Emerge trial patients showed an average 87% decrease from baseline on the NPI, and their caregivers reported an 84% decrease in distress. Of those who
completed the Emerge trial, patients who received placebo
experienced a 22% greater decrease in CDR-SB relative to
participants who received high-dose aducanumab. Furthermore, Emerge and Engage patients that received at least 14
doses of high-dose aducanumab showed average delays in
lowering of CDR-SB by 30% and 27%, respectively.50 Aducanumab was also found to significantly improve scores in
ADAS-Cog13, however, it did not improve MMSE with statistical significance.47 All patients receiving aducanumab
experienced an average 40% mitigation of loss of ability to
carry out daily living relative to patients receiving placebo,
according to ADCS-ADL scores.50

A major concern regarding aducanumab’s phase III clinical
trials is both were halted roughly half-way in March 2019
because of failure to significantly improve AD symptoms.49
Neither Engage nor Emerge showed significant improvement
in patients’ CDR-SB scores, and each study’s findings met
pre-determined futility criteria.48,49,51 However, months
later more participants finished each trial, and supplementary data from these patients made it such that Emerge
patients experienced significant benefit from aducanumab
treatment according to CDR-SB scores. The high-dose
group in the Emerge trial met its primary goal and established significance after the data was supplemented (P =
0.01).52 After post hoc analysis, Engage still did not meet
primary outcomes.48,49 Possible confounding variables
identified for the Engage trial include fewer individuals who
received high-dose aducanumab and increased number of
outliers who experienced dramatic worsening of symptoms.51 The incongruence of these studies after post hoc
analysis has sparked debate as to the drug’s efficacy with
some calling for further clinical trials. In November 2020,
an FDA advisory committee voted the evidence from the
Emerge and Engage trials did not provide strong evidence
that aducanumab has shown effectiveness in the treatment
of AD.51,52
Another concern is that the benefit in cognitive function
observed in patients from the Emerge trial may not be clinically significant. A 2019 study established that for treatment for AD to reach clinical significance, it must show an
average difference of at least 1 point in CDR-SB for MCI patients and 2 points for patients with mild AD.53 Based on
data released by Biogen on October 22, 2019, the results
from high-dose groups in both Emerge and Engage did not
reach a 1 point difference.48 Also, aducanumab had significant improvement of CDR-SB and ADCS-ADL scores, but
these improvements had effect sizes of < 0.2 indicating minor clinical changes.47 These improvements do indicate
that aducanumab could enhance both cognition and daily
living in patients with MCI or mild AD, however, the magnitude of this drug’s benefit may only be statistically significant and not clinically significant.51–53
PATIENT SAFETY

In clinical trials, aducanumab has been associated with various side effects. The most common side effects reported
include headache, diarrhea, and other constitutional symptoms.35,44,47 One of the most severe major side effects of
all anti-Aβ monoclonal antibody therapies, including aducanumab, is ARIA-E.45–47 A meta-analysis by Avgerinos et
al47 determined that among 3 other anti-Aβ antibody immunotherapies, aducanumab is associated with the greatest risk of developing ARIA-E. Notably, although there have
been deaths associated with other anti-Aβ immunotherapy
treatments such as bapinezumab and solanezumab, there
have been no deaths associated with the use of aducanumab
to treat AD.44–46
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CONCLUSION
Pre-clinical studies and clinical trials have suggested the
ability of aducanumab to restore neurological function in
patients with AD by reducing Aß plaques and reestablishing
neuronal calcium permeability.42,43 However, discrepancy
in post hoc analysis findings have cast doubt amongst the
research and medical community. Some studies suggest the
benefits of aducanumab are perhaps limited to statistical
significance and lack clinical significance.51–53 In contrast,
other studies argue the FDA vote for the denial of aducanumab stemmed from a narrow perspective failing to take
other aspects into consideration.50 While it’s possible confounding variables played a role in the difference seen between the Emerge and Engage trials, the observed incongruency has emphasized the need for repeated trials to increase
confidence.51 Despite the persistent skepticism in clinical
efficacy, aducanumab has proven to significantly decrease
amyloid in all cortical brain regions examined.34,35 In summary, aducanumab has provided hope for those working toward the goal of providing patients a safe and viable treatment option in the management of AD.
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Table 1. Clinical Efficacy and Safety
Author
(Year)

Purpose and Intervention

Results and Findings

Conclusions

Alexander
et al.52
(2021)

The efficacy of aducanumab for the
treatment of AD is evaluated using
outcomes from aducanumab’s phase I
and phase III clinical trials.

After supplementary data was incorporated
following phase III trials being halted,
Emerge met its primary goal (P = 0.01). An
FDA advisory committee voted by majority
that results from Emerge and Engage failed to
demonstrate that aducanumab deserved
FDA approval. The post hoc analyses for
Engage and Emerge increase the likelihood of
introduction of bias into data review and
interpretation.

Data from Emerge
and Engage may
not provide
enough evidence
to support FDA
approval of
aducanumab to
outweigh the fact
that both trials
were halted for
evidence of futility.

Avgerinos
et al.47
(2021)

This meta-analysis and systematic
review evaluated the risks and
benefits associated with phase III
clinical trials using monoclonal antiAß antibodies for the treatment of
AD. Data from 17 studies (2 on
gantenerumab, 3 on solanezumab, 6
on bapineuzumab, and 4 on
aducanumab) involving 12 phase III
clinical trials are included.

Aducanumab was found to have the
greatest risk of ARIA-E of any anti-Aß
immunotherapeutic antibody developed.
Aducanumab is the only monoclonal anti-Aß
antibody that has been found to significantly
reduce Aß PET SUVR (P < 0.05).
Aducanumab improved patient CDR-SB and
ADCS-ADL scores with an effect size of <
0.2.

Aducanumab
showed the most
benefit in treating
AD pathology and
symptoms among
the anti-Aß
antibodies
available based on
biomarker and
clinical symptom
improvement.

Cummings
et al.50
(2021)

Data from aducanumab’s Phase III
Engage and Emerge trials are
compared to findings from other
phase III AD-modifying monoclonal
antibody drug trials.

Patients receiving high-dose aducanumab in
the Emerge trial experienced an 87%
decrease from baseline in NPI. High-dose
patients in the Emerge trial also experienced
a ~40% improvement in ADCS-ADL score
relative to placebo patients. Trials for other
anti-Aß monoclonal antibodies for the
treatment of AD have shown dosedependent effects like the pattern observed
in the Emerge trial.

The Emerge trial
demonstrated
clinical benefit in
the treatment of
AD, and its findings
are supported by
findings in similar
studies.

Knopman
et al.49
(2021)

The significance of findings from
Engage and Emerge are evaluated.

Both Emerge and Engage showed a dosedependent reduction in size of Aß plaques
relative to placebo based on PET SUVR (P <
0.001). After post-hoc analysis, Emerge met
its primary target in reducing cognitive
decline while Engage did not.

Another Phase III
clinical trial may be
necessary to
confirm the
efficacy of highdose aducanumab
demonstrated in
the Emerge trial.

Kuller and
Lopez51
(2021)

The validity of findings from Engage
and Emerge is determined. Further
steps in verification of aducanumab
as a therapy for AD are examined.

Emerge is the first phase III clinical trial
where an anti-Aß monoclonal antibody
immunotherapy has been able to show
slowing of cognitive impairment in patients
suffering from AD or MCI. Possible
confounding variables in Engage were
identified including a lower number of highdose patients and the presence of outliers.

Patients from the
Engage and Emerge
trials should be
evaluated longterm to observe
the effects of
aducanumab.
Another phase III
clinical trial using
high-dose
aducanumab is
warranted.

Howard
and Liu48
(2020)

The validity of interpretations from
phase I and phase III trials regarding
aducanumab for the treatment of AD
is analyzed.

To show significant clinical benefit, AD
treatment must show an average difference
in CDR-SB score of 1 point for patients with
MCI and 2 points for patients with mild AD.
Neither high-dose group from Engage nor
Emerge reached a 1-point difference from
placebo patients. Aducanumab’s efficacy at
degrading Aß plaques was supported in both
phase III trials.

Phase III clinical
trials for
aducanumab did
not show clinically
significant benefit
for AD patients in
terms of CDR-SB
score.

Tian Hui
Kwan et
al.46 (2020)

Findings from multiple Aß-targeted
monoclonal antibody therapies that
entered phase III clinical trials are
compared. These drug therapies

Aducanumab was found to have positive
dose-dependent clinical benefit in its Phase
Ib study. Data from high-dose aducanumab
patients in the Emerge and Engage trials

Aducanumab’s
Engage and Emerge
trials show
conflicting results,
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include crenezumab, gantenerumab,
solanezumab, and aducanumab.

showed an average improvement in CDR-SB
of 23% (P = 0.010) and -2% (P = 0.825)
respectively. The average score
improvement in CDR-SB observed in
patients in the Emerge trial was by a score of
0.4 points on an 18-point scale.

and the Emerge
trial’s findings may
be of little clinical
significance.

Mo et al.45
(2017)

This meta-analysis and systemic
review evaluates the safety and
efficacy of monoclonal anti-Aß
antibodies for the treatment of AD.

ARIA-E was one of the most reported side
effects, but no deaths were reported in the
Phase Ib clinical trial for aducanumab.
Aducanumab significantly improved MMSE
scores in patients with MCI or mild AD
relative to placebo in the Prime trial.
Aducanumab was not found to significantly
improve patients’ DAD or ADAS-cog13
scores.

Aducanumab’s
phase Ib clinical
trial showed that
aducanumab may
help prevent
cognitive decline
in AD patients and
significantly
increase one’s risk
of developing
ARIA-E.

Gamage
and
Kumar43
(2017)

The role of calcium dysregulation in
neurodegenerative disorders, such as
AD, and how aducanumab may alter
dysfunction.

Aß plaques increase the clearance of NMDA
receptors from neurons’ cell surfaces, which
contributes to disruption in Ca2+
permeability. Aducanumab has been able to
decrease Aß plaque size in human and
mouse trials. Aducanumab was found to
significantly recover SERCA pump
regulation which was disrupted in
transgenic mice with Aß plaques (P < 0.001).

Aducanumab may
improve
neurological
function in
patients with
neurodegenerative
diseases caused by
Aß plaques by
restoring function
of NMDA
receptors and
SERCA pumps.

Kastanenka
et al.42
(2016)

Transgenic mice overexpressing
amyloid precursor protein were
grown and treated acutely with
topical administration of an
aducanumab analog directly to the
brain (0.42-1 mg/ml) or were treated
weekly with 10 mg/kg aducanumab
for 6 months. Each mouse’s brain was
imaged using fluorescent microscopy
to tag Aß plaques, and biomarkers
were measured before and after
treatment.

Acute topical treatment with aducanumab
analog significantly reduced the number of
Aß plaques at a greater rate than the
reduction observed in control mice (P <
0.0001). Chronic treatment with
aducanumab analog did not show significant
reduction in the number of Aß plaques (P =
0.35). Mice that received chronic treatment
had a lower incidence of calcium overload (P
< 0.05) and increased calcium permeability
relative to controls (P < 0.05).

Aducanumab may
decrease the rate
of cognitive
decline in AD
patients not only
by degradation of
Aß plaques but by
re-establishing
physiological
intracellular
calcium levels.

Ferrero et
al.44 (2016)

Aducanumab was studied in a singledose-escalation, placebo-controlled,
randomized, double-blind phase I
clinical study. This study included 53
patients with mild or moderate AD
who received placebo or 0.3, 1, 3, 10,
20, 30, or 60 mg/kg doses of
aducanumab and were followed up to
24 weeks after receiving treatment.

All 3 patients who received 60 mg/kg of
aducanumab developed ARIA-E which
ultimately resolved. Pharmacokinetic
findings indicated that increasing dosage did
not alter the rate of clearance, half-life, or
volume of distribution of aducanumab.
ARIA-E was the most severe adverse effect
observed, with most other adverse effects
being constitutional complaints.

The only observed
severe adverse
effect in this study
was ARIA-E which
has been
associated with
other monoclonal
anti-Aß antibody
immunotherapies.

Sevigny et
al.35 (2016)

Aducanumab was studied in a
placebo-controlled, randomized,
double-blind phase Ib trial including
165 patients. These participants with
MCI or mild AD were administered 1,
3, 6, or 10 mg/kg of aducanumab
monthly for 12 months.

Aducanumab reduced cognitive decline in
AD patients that received 3 or 10 mg/kg of
aducanumab based on MMSE (P < 0.05).
41% of participants receiving 10 mg/kg
aducanumab developed ARIA-E. PET SUVR
score was lowered relative to baseline in
patients that received 10, 6, and 3 mg/kg of
aducanumab (P < 0.001).

Aducanumab
sufficiently crosses
the BBB to aid in
the degradation of
Aß plaques in a
dose-dependent
manner in AD
patients.

Key: Alzheimer’s Disease (AD); Food and Drug Administration (FDA); beta-amyloid (Aβ); Alzheimer’s related imaging abnormality-edema/effusion (ARIA-E); Positron Emission Tomography (PET); standard uptake volume ratio (SUVR); Clinical Dementia Rating Scale-sum of boxes (CDR-SB); Alzheimer’s Disease Cooperative Study - Activities of Daily Living
(ADCS-ADL); neuropsychiatric inventory (NPI); mild cognitive impairment (MCI); mini mental state examination (MMSE); disability assessment for dementia (DAD); Alzheimer’s Disease assessment scale-cognitive subscale 13 (ADAS-cog13); N-methyl-D-aspartate (NMDA; sarcoendoplasmic reticulum calcium ATPase (SERCA); blood brain barrier (BBB)
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